Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Neoadjuvant Chemotherapy for Ovarian Cancer

November 26th 2014

Timing of Oophorectomy in Ovarian Cancer

November 26th 2014

Prophylactic Oophorectomy for Reducing Ovarian Cancer Risk

November 26th 2014

Universal Screening for BRCA1 and BRCA2 Mutations

November 26th 2014

Dr. Wright Discusses the Molecular Biology of Ovarian Cancer

November 25th 2014

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the molecular biology of ovarian cancer.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

FDA Approves Bevacizumab for Recurrent Ovarian Cancer

November 14th 2014

The FDA has approved bevacizumab in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

New Research Focuses on Personalized Treatments in Ovarian Cancer

November 6th 2014

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

Safra Provides an Overview of PARP Inhibitors in Ovarian Cancer

November 6th 2014

PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.

Trebananib Misses Survival Goal in Phase III Ovarian Cancer Study

November 4th 2014

The combination of paclitaxel and the angiogenesis inhibitor trebananib did not demonstrate a statistically significant improvement in overall survival when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.

Promising Treatments on Horizon in Ovarian Cancer

October 16th 2014

The treatment of women with advanced ovarian cancer is set to undergo a substantial transformation, due to an explosion of clinical trials exploring novel treatment options.

New Method Explored for Personalized Vaccines for Ovarian Cancer

October 16th 2014

A new method to identify protein mutations in cancer cells may help researchers create a personalized vaccine to treat patients with recurrent ovarian cancer.

Olaparib in Ovarian Cancer

October 9th 2014

Maurie Markman on Patient-Centered Cancer Care

October 9th 2014

Herbert Irving Comprehensive Cancer Center

October 9th 2014

Latest News & Insight: October 9, 2014

October 9th 2014

2014 ESMO Congress Highlights

October 9th 2014